Review
. 2014 Nov; 28 Suppl 3:6-14.

CTLA-4 antibodies: new directions, new combinations

Samuel A Funt  David B Page  Jedd D Wolchok  Michael A Postow  
  • PMID: 25387681
  •     15 citations

Abstract

Checkpoint blockade is a transformative therapeutic approach to a broad spectrum of malignancies because it increases the power of antitumor immunity to obtain durable responses. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is the prototypical inhibitory checkpoint receptor. Since US Food and Drug Administration approval of the anti-CTLA-4 antibody ipilimumab for use in patients with melanoma, there has been ever-increasing excitement among oncologists about new ways to use this method of releasing the "brakes" on patients' endogenous immune systems. This review will summarize the preclinical and clinical development of CTLA-4-blocking antibodies, discuss recent insights into the biology of CTLA-4 blockade, review the use of these antibodies in combination with established and novel therapeutic modalities, and comment on ongoing questions regarding their administration.

Other Links

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.
William C Reinhold, Margot Sunshine, +2 authors, Yves Pommier.
Clin Cancer Res, 2015 Jun 07; 21(17). PMID: 26048278    Free PMC article.
Review.
Trends and advances in tumor immunology and lung cancer immunotherapy.
Mohanad Aldarouish, Cailian Wang.
J Exp Clin Cancer Res, 2016 Oct 01; 35(1). PMID: 27686848    Free PMC article.
Review.
PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach.
Daniela D'Arcangelo, Francesco Facchiano, +11 authors, Antonio Facchiano.
Oncotarget, 2016 Oct 21; 7(47). PMID: 27764787    Free PMC article.
Immune Checkpoints as a Target for Colorectal Cancer Treatment.
Alessandro Passardi, Matteo Canale, Martina Valgiusti, Paola Ulivi.
Int J Mol Sci, 2017 Jun 22; 18(6). PMID: 28635639    Free PMC article.
Review.
Immune checkpoint inhibitors in cancer therapy.
Eika S Webb, Peng Liu, +3 authors, Yao-He Wang.
J Biomed Res, 2017 Sep 04; 32(5). PMID: 28866656    Free PMC article.
Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.
Ernesto Mejías-Pérez, Liliana Carreño-Fuentes, Mariano Esteban.
Mol Ther Oncolytics, 2018 Jan 26; 8. PMID: 29367944    Free PMC article.
Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors.
Vishal Jindal, Sorab Gupta.
Mol Neurobiol, 2018 Feb 01; 55(8). PMID: 29383686
Review.
Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model.
Avner Friedman, Xiulan Lai.
PLoS One, 2018 Feb 09; 13(2). PMID: 29420595    Free PMC article.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.
Xiulan Lai, Andrew Stiff, +3 authors, Avner Friedman.
Proc Natl Acad Sci U S A, 2018 May 08; 115(21). PMID: 29735668    Free PMC article.
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents.
Paola Ciciola, Priscilla Cascetta, +2 authors, Roberto Bianco.
J Clin Med, 2020 Mar 07; 9(3). PMID: 32138216    Free PMC article.
Review.
Testing Possible Risk Factors for Idiosyncratic Drug-Induced Liver Injury Using an Amodiaquine Mouse Model and Co-treatment with 1-Methyl-d-Tryptophan or Acetaminophen.
Tiffany Cho, Lie Yun Kok, Jack Uetrecht.
ACS Omega, 2021 Mar 02; 6(7). PMID: 33644572    Free PMC article.
The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses.
Guanglin Cui.
Front Oncol, 2021 Mar 26; 11. PMID: 33763344    Free PMC article.
Review.
Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Ernesto Rossi, Melissa Bersanelli, +8 authors, Paolo Andrea Zucali.
Curr Oncol Rep, 2021 Nov 09; 23(12). PMID: 34748099    Free PMC article.
Review.
Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
Nourridine Siewe, Avner Friedman.
PLoS One, 2022 Jan 12; 17(1). PMID: 35015785    Free PMC article.